Eris Lifesciences Limited

10%

and H1 DBF EBIDTA – Q2 and H1 • DBF EBIDTA performance • DBF EBIDTA performance • Q2 growth of 10% yoy – 30% over • Q2 growth of 10% yoy - 30% over IPM growth of 7.7% IPM growth of 7.7% • H1 gr

30%

BF EBIDTA – Q2 and H1 • DBF EBIDTA performance • DBF EBIDTA performance • Q2 growth of 10% yoy – 30% over • Q2 growth of 10% yoy - 30% over IPM growth of 7.7% IPM growth of 7.7% • H1 growth of 11

7.7%

performance • Q2 growth of 10% yoy – 30% over • Q2 growth of 10% yoy - 30% over IPM growth of 7.7% IPM growth of 7.7% • H1 growth of 11% yoy – 42% over • H1 growth of 11% yoy - 42% over IPM gro

11%

0% over • Q2 growth of 10% yoy - 30% over IPM growth of 7.7% IPM growth of 7.7% • H1 growth of 11% yoy – 42% over • H1 growth of 11% yoy - 42% over IPM growth of 7.4% IPM growth of 7.4% • Key m

42%

Q2 growth of 10% yoy - 30% over IPM growth of 7.7% IPM growth of 7.7% • H1 growth of 11% yoy – 42% over • H1 growth of 11% yoy - 42% over IPM growth of 7.4% IPM growth of 7.4% • Key misses in d

7.4%

rowth of 7.7% • H1 growth of 11% yoy – 42% over • H1 growth of 11% yoy - 42% over IPM growth of 7.4% IPM growth of 7.4% • Key misses in delivering “50% revenue • Key misses in delivering "50% reven

50%

growth of 11% yoy - 42% over IPM growth of 7.4% IPM growth of 7.4% • Key misses in delivering “50% revenue • Key misses in delivering "50% revenue growth over market" as guided growth over marke

13%

c-25) and full impact of price increases impact of price increases • Growth of 11% yoy in Q2 and 13% • Growth of yoy in H1 yoy in H1 yoy in Q2 and • Margin expansion by 32 bps yoy to • Margin ex

32 bps

h of 11% yoy in Q2 and 13% • Growth of yoy in H1 yoy in H1 yoy in Q2 and • Margin expansion by 32 bps yoy to • Margin expansion by 32 bps yoy to 37.6% in Q2 and by 93 bps yoy to 37.6% in Q2 and by 9

37.6%

oy in H1 yoy in Q2 and • Margin expansion by 32 bps yoy to • Margin expansion by 32 bps yoy to 37.6% in Q2 and by 93 bps yoy to 37.6% in Q2 and by 93 bps yoy to 373% in H1 37.3% in H1 • EBIDTA hit

93 bps

and • Margin expansion by 32 bps yoy to • Margin expansion by 32 bps yoy to 37.6% in Q2 and by 93 bps yoy to 37.6% in Q2 and by 93 bps yoy to 373% in H1 37.3% in H1 • EBIDTA hit of Rs. 5+ cr. in Q2

373%

gin expansion by 32 bps yoy to 37.6% in Q2 and by 93 bps yoy to 37.6% in Q2 and by 93 bps yoy to 373% in H1 37.3% in H1 • EBIDTA hit of Rs. 5+ cr. in Q2 on • EBIDTA hit of Rs. 5+ cr. in Q2 on accou